# Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents for Diffuse Long Coronary Artery Disease

Study · id `cardio:ct-nct02831205` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02831205](<https://clinicaltrials.gov/study/NCT02831205>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02831205

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It plans to enroll 800 participants.

## Technical summary

Registry record NCT02831205. Randomized; no masking; primary purpose treatment. Start 2016-07 (registry gives no type); primary completion 2017-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 800 participants (planned count; ClinicalTrials.gov record NCT02831205, source copy `cardio:ctgov-nct02831205-2017-12-15`, retrieved 2026-10-26)
- Start date: 2016-07 (registry gives no type) (ClinicalTrials.gov record NCT02831205, source copy `cardio:ctgov-nct02831205-2017-12-15`, retrieved 2026-10-26)
- Primary completion: 2017-12 (actual) (ClinicalTrials.gov record NCT02831205, source copy `cardio:ctgov-nct02831205-2017-12-15`, retrieved 2026-10-26)
- Completion: 2017-12 (actual) (ClinicalTrials.gov record NCT02831205, source copy `cardio:ctgov-nct02831205-2017-12-15`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT02831205, source copy `cardio:ctgov-nct02831205-2017-12-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02831205-2017-12-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents for Diffuse Long Coronary Artery Disease
- Acronym: ABSORB-LONG
- Condition: Percutaneous Transluminal Coronary Angioplasty
- Intervention (Device): everolimus-eluting bioresorbable vascular (Absorb) scaffold
- Intervention (Device): everolimus-eluting cobalt-chromium (Xience) stent
- Lead sponsor: Duk-Woo Park, MD
- Lead sponsor class: OTHER
- Collaborator: CardioVascular Research Foundation, Korea
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Duk-Woo Park, MD (`cardio:org-duk-woo-park-md`)
- Registry lists this organization as a collaborator: CardioVascular Research Foundation, Korea (`cardio:org-cardiovascular-research-foundation-korea`)

## Provenance

Content hash: d0027144fb1e75534faeb489392bd0bdb6f2dacf9c17fb4d166e2aa001982472
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
